Back to today’s briefing

Story perspectives

Mysimba Shows Promise, But Cardiovascular Safety Concerns Remain

3/31/2025

26 5

Summary

Story summary

Mysimba, a weight management drug, demonstrates a promising benefit-risk profile, yet concerns linger about its cardiovascular safety beyond one year. A recent study by Currax, monitoring Mysimba patients for over 4.7 years, found no increased cardiovascular risk. However, further investigation is essential to ensure its long-term safety for users.

1 of 1

Story summary

Mysimba, a weight management drug, demonstrates a promising benefit-risk profile, yet concerns linger about its cardiovascular safety beyond one year. A recent study by Currax, monitoring Mysimba patients for over 4.7 years, found no increased cardiovascular risk. However, further investigation is essential to ensure its long-term safety for users.